Cosentyx (secukinumab) / Novartis - LARVOL DELTA

P162 Evaluation of a remote tertiary hub-and-spoke model for the approval of high-cost drugs in medical dermatology. (PubMed, Br J Dermatol) - "Eighteen referrals were for HS: 11 for use of adalimumab and 7 for secukinumab. With HS affecting > 200 000 people in the UK, and more therapies being approved for use, it is conceivable that local decision making may become more appropriate, and these results suggest clinicians feel confident making such decisions. Tertiary discussion for rituximab use seemed to be deemed appropriate by users."

Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Pemphigus Vulgaris • Psoriasis

P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa. (PubMed, Br J Dermatol) - "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."

Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome

SG14 Homozygous pathogenic variant in transgradient palmoplantar keratoderma: causative, contributory or irrelevant? (PubMed, Br J Dermatol) - "He is currently managed on acitretin 25 mg once daily and psoralen plus ultraviolet A. Acitretin at 50 mg alone was effective but was discontinued due to side-effects. Previous treatment with secukinumab and adalimumab was not beneficial...However, 10% of individuals with European ancestry are heterozygous carriers of loss-of-function variants in the FLG gene. This high carrier frequency in the general population suggests that FLG may be only a contributing factor, and other variants or environmental factors are important in the manifestation of PPK, if FLG variants are found in so many unaffected individuals."

Journal • Asthma • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pulmonary Disease • Respiratory Diseases • Vitiligo • FLG

P089 Efficacy of tofacitinib in cases of moderate-to-severe (stage 2 and stage 3) hidradenitis suppurativa: a pilot study. (PubMed, Br J Dermatol) - "Treatment options are limited, and existing therapies like adalimumab and secukinumab show inconsistent results. In conclusion, tofacitinib showed significant potential in treating moderate-to-severe HS, improving disease severity, quality of life and associated inflammation. These promising findings highlight the need for more extensive trials with controls to confirm its safety and efficacy."

Journal • Dermatology • Fibrosis • Hidradenitis Suppurativa • Immunology • Inflammation • Pain • IL6

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

O05 A retrospective review of cases of psoriasis requiring discontinuation of biologic therapy from 2007 to 2024 in a multisite NHS trust. (PubMed, Br J Dermatol) - "Concurrent systemic immunosuppression (methotrexate or ciclosporin) was prescribed in 21% (n = 31)...The biologics with most interventions were adalimumab or biosimilars (n = 102: Humira n = 39, Idacio n = 30, Hyrimoz n = 23, Amgevita n = 10), ustekinumab (n = 39), secukinumab (n = 35), guselkumab (n = 13) and certolizumab (n = 11)...The main blood abnormality was positive tuberculosis ELISpot assay (interferon-γ release assay) (n = 6: Humira n = 2; and Idacio, ustekinumab, etanercept and risankizumab n = 1 each). Other abnormalities included leucocytosis in sepsis (n = 2; ustekinumab, secukinumab), neutropenia (n = 1; Hyrimoz), raised alanine aminotransferase (n = 1; Humira) and raised fetal calprotectin (n = 1; Ixekizumab)...Blood abnormalities requiring treatment intervention were infrequent, most commonly positive tuberculosis testing. Our findings support reducing blood monitoring of..."

Journal • Retrospective data • Atopic Dermatitis • Dermatology • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Hidradenitis Suppurativa • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Neutropenia • Pain • Psoriasis • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Septic Shock • Seronegative Spondyloarthropathies • Tuberculosis • Type 2 Diabetes Mellitus • Ulcerative Colitis • Urticaria • IFNG

P099 Spesolimab use in effective treatment of generalized pustular psoriasis: a case report. (PubMed, Br J Dermatol) - "He was managed as an inpatient with topical treatment and oral prednisolone...He received oral methotrexate therapy but upon readmission with pustulation flare, diagnosis of GPP was confirmed and acitretin commenced...The patient then experienced widespread desquamative eruption and incipient pustulation, and as it was not possible to secure further compassionate funding for spesolimab as maintenance therapy, he commenced secukinumab therapy...In our patient with GPP spesolimab was a highly effective treatment modality, leading to lasting skin clearance when used as monotherapy from its induction, but unavailable for maintenance therapy. We await NICE appraisal, due March 2025, to consider its use within NHS care."

Journal • Dermatology • Gastroenterology • Hepatology • Immunology • Keratitis • Pancreatitis • Psoriasis • Pustular Psoriasis

What is the optimal sequential therapy after secondary IL-17A inhibitor failure in psoriasis: switching to an IL-23 inhibitor or to another IL-17A inhibitor? (PubMed, J Dermatolog Treat) - "This single-center, retrospective analysis included psoriatic patients who experienced secondary failure to either ixekizumab or secukinumab and subsequently switched to another IL-17A inhibitor (ixekizumab or secukinumab; intraclass switching group) or to an IL-23 inhibitor (guselkumab; interclass switching group). Previous exposure to ≥2 biologics working on different pathways was identified as a risk factor for treatment failure in the interclass switching group. An intraclass switch following IL-17A inhibitors failure yielded better treatment outcomes than a switch to guselkumab."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Secukinumab in Moderate-to-Severe Graves' Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. (PubMed, J Clin Endocrinol Metab) - "Secukinumab did not show clinical efficacy versus placebo when treating patients with active, moderate-to-severe GO."

Clinical • Journal • Fibrosis • Immunology • Inflammation • Ophthalmology • Thyroid Eye Disease • IL17A

Time to lift the moratorium on IL-23 inhibitors for axial psoriatic arthritis. (PubMed, Lancet Rheumatol) - "However, post-hoc analyses of clinical trials show clinical improvements in axial psoriatic arthritis following treatment with ustekinumab, guselkumab, and risankizumab...Furthermore, inadequate response to biological therapies in axial spondyloarthritis was associated with absence of MRI-determined bone marrow oedema, whereas responses to secukinumab in axial spondyloarthritis were independent of bone marrow oedema, pointing to divergent pathophysiological processes. The growing recognition of clinical, microanatomical, and immunological differences between axial spondyloarthritis and axial psoriatic arthritis suggests differential IL-23 pathway dependence. This Personal View aims to provide a deeper examination of these distinctions as a basis to propose reconsidering the current moratorium on IL-23 inhibitors-particularly in phenotypes not linked to HLA-B27-and to potentially expand therapeutic options."

Journal • Review • Ankylosing Spondylitis • Immunology • Inflammation • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL23A

Scaphoid nonunion in the presence of a Scapho-Lunate coalition: a rare case report. (PubMed, Arch Orthop Trauma Surg) - "This is the first reported case of scaphoid pseudarthrosis associated with an SL coalition. The case highlights therapeutic dilemmas in coalition-related fractures: distal scaphoid resection risks midcarpal instability, whereas reconstruction faces an increased risk of nonunion due to altered biomechanics. Successful consolidation demonstrates that standard reconstructive techniques remain feasible and underscores the importance of recognizing coalitions as risk factors for nonunion in surgical planning."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoarthritis • Pain

The complex interplay between psoriasis and depression: from molecular mechanisms to holistic treatment approaches. (PubMed, Front Immunol) - "Biologics (e.g., adalimumab, secukinumab, and guselkumab) can simultaneously ameliorate skin lesions and depressive symptoms. When combined with psychological interventions-including cognitive behavioral therapy and mindfulness therapy-a multidisciplinary collaboration involving dermatology, rheumatology, and psychology is essential to formulate a tailored treatment plan. This review systematically outlines the core mechanisms underlying comorbidity of these two diseases, as well as multidimensional treatment strategies."

Journal • Review • CNS Disorders • Depression • Dermatology • Immunology • Inflammation • Mood Disorders • Psoriasis • Psychiatry • Rheumatology • CXCL8 • IL6

Harnessing Glutamine-117 Plasticity toward Structure-Based Identification of Triazole IL-17 Inhibitors. (PubMed, J Med Chem) - "Antibody-based IL-17 inhibitors like secukinumab (Cosentyx) have demonstrated clinical success in psoriasis, psoriatic arthritis, and ankylosing spondylitis, sparking efforts to develop orally bioavailable small molecule alternatives...A structure-based library approach, considering the high plasticity of the Gln117 side chain, yielded structurally diverse Trp90 pocket binding motifs. The X-ray structures of the most potent hits guided subsequent optimization, resulting in triazole-based IL-17 inhibitors with low nanomolar cellular activity, which are promising leads for further development."

Journal • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Exploring Reasonable Extension of Secukinumab Dosing Intervals in Real-World Settings. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Psoriasis

Real-World Evidence of Secukinumab and Bimekizumab in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. (PubMed, Actas Dermosifiliogr) - "IL-17 inhibitors provide moderate response rates and are valuable options for patients refractory to other therapies, with low incidences of mild adverse events. More RWE studies are essential to better understand their safety and efficacy profile."

Clinical • HEOR • Journal • Real-world evidence • Retrospective data • Dermatology • Hidradenitis Suppurativa • Immunology • Pain • IL17A

Efficacy and Safety of Biologics in the Treatment of Pediatric Psoriatic Arthritis: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal • Dermatology • Immunology • Inflammatory Arthritis • Pediatrics • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Case Report: Acute generalized exanthematous pustulosis with psoriasis successfully treated with Secukinumab. (PubMed, Front Immunol) - "Herein we firstly reported a 56-year-old man with severe plaque psoriasis who developed metamizole-induced AGEP during a clinical trial for BEBT-305 (HSP90 inhibitor) that was successfully treated with Secukinumab. Biologics should be considered in patients with AGEP, especially those with a history of psoriasis. This can benefit both diseases."

Journal • Allergy • Dermatology • Immunology • Pruritus • Psoriasis • Pustular Psoriasis • CDC37 • CRP

Upadacitinib in the treatment of SAPHO syndrome: a case report. (PubMed, Front Immunol) - "After ineffective treatment with secukinumab (an IL-17A inhibitor), transitioning to upadacitinib (a selective JAK1 inhibitor) improved pustular lesions and reduced joint pain and inflammation, demonstrating clinical improvement. This case illustrates the effectiveness of upadacitinib, a selective JAK1 inhibitor, for the rapid resolution of cutaneous and articular symptoms of SAPHO syndrome following unsuccessful IL-17A inhibition, offering valuable insights for management of refractory SAPHO syndrome."

Journal • Acne Vulgaris • Dermatology • Immunology • Inflammation • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Pain • Psoriasis • IL17A

Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS (clinicaltrials.gov) - P4 | N=30 | Not yet recruiting | Sponsor: Peking Union Medical College

New P4 trial • Acne Vulgaris • Dermatology • Hidradenitis Suppurativa • Immunology

Treatment responses and relapse predictors in pediatric CNO: insights from a referral center. (PubMed, Rheumatology (Oxford)) - "Conventional DMARDs are effective in a limited subset of CNO patients, who may represent a milder disease phenotype. The presence of skin involvement and a greater number of affected bones may both suggest a more aggressive disease course. Anti-TNF therapies are the most effective agents, while other biologics offer promising results in resistant cases. Prospective studies are needed to guide individualized treatment strategies."

Journal • Fatigue • Inflammation • Musculoskeletal Pain • Pain • Pediatrics

GigAINt: Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission (clinicaltrials.gov) - P3 | N=151 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2026 ➔ Jul 2026 | Trial primary completion date: Nov 2026 ➔ Feb 2026

Monotherapy • Trial completion date • Trial primary completion date • Giant Cell Arteritis • Immunology • CRP

PROMPT: 2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (clinicaltrials.gov) - P=N/A | N=127 | Completed | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Completed

HEOR • Trial completion • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

A Case of Secukinumab in the Treatment of Psoriasis-Like Cutaneous Chronic Graft-versus-Host Disease. (PubMed, Case Rep Dermatol) - "After 3 months of treatment, the cutaneous lesions had substantially resolved, with no reported adverse effects. Anti-IL-17A monoclonal antibody therapy may represent an alternative treatment modality for cGVHD patients presenting with psoriatic phenotypes."

Journal • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dermatitis • Dermatology • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Immunology • Oncology • Psoriasis • Transplantation • IL17A

Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report. (PubMed, Front Med (Lausanne)) - "Secukinumab may provide potential clinical benefits with an acceptable safety profile in infants with GPP. Further research is required to establish the optimal treatment duration, dosing intervals, and long-term safety in this population."

Journal • Dermatology • Dermatopathology • Immunology • Pruritus • Psoriasis • Pustular Psoriasis

New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report. (PubMed, Case Rep Gastroenterol) - "Before starting an anti-IL-17 agent, physicians should review the patient's personal and family history of IBD, as well as other risk factors, including immune-mediated conditions such as MS that may increase IBD risk. Patients should then be closely monitored for the development of any new GI symptoms."

Journal • Ankylosing Spondylitis • CNS Disorders • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Multiple Sclerosis • Psoriasis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis